• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

IRLAB Therapeutics

1.39 SEK

+6.41 %

Less than 1K followers

IRLAB A

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+6.41 %
+12.35 %
-0.10 %
-29.82 %
-27.69 %
-61.50 %
-81.19 %
-96.38 %
-86.99 %

IRLAB Therapeutics is a Swedish research and pharmaceutical company. The research is based on the company's own research platform and specializes in the treatment of brain diseases, commonly referred to as neurodegenerative diseases. At the present, the company holds drug candidates specializing in, among other things, Parkinson's disease. The head office is located in Gothenburg.

Read more
Market cap
207.3M SEK
Turnover
1M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.8.
2026

Interim report Q2'26

11.11.
2026

Interim report Q3'26

12.2.
2027

Annual report '26

Regulatory press release30.06.2026 klo 18.10

Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB

IRLAB Therapeutics
Regulatory press release29.06.2026 klo 21.45

IRLAB’s rights issue was oversubscribed and the company resolves on allotment in the overallotment issue

IRLAB Therapeutics
Press release16.06.2026 klo 08.00

IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies

IRLAB Therapeutics

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release11.06.2026 klo 09.45

The subscription period in IRLAB’s rights issue commences today

IRLAB Therapeutics
Regulatory press release05.06.2026 klo 17.00

IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received

IRLAB Therapeutics
Regulatory press release05.06.2026 klo 14.50

Report from the Extraordinary General Meeting of IRLAB Therapeutics AB

IRLAB Therapeutics
Press release03.06.2026 klo 08.00

IRLAB participates at Aktiedagarna in Stockholm on June 9.

IRLAB Therapeutics
Regulatory press release06.05.2026 klo 08.00

IRLAB publishes interim report for the period January - March 2026

IRLAB Therapeutics
Regulatory press release05.05.2026 klo 10.03

KALLELSE TILL EXTRA BOLAGSSTÄMMA I IRLAB THERAPEUTICS AB

IRLAB Therapeutics
Regulatory press release05.05.2026 klo 09.41

IRLAB resolves on a rights issue of approximately SEK 68 million with an overallotment issue and obtains extended loan financing

IRLAB Therapeutics
Press release30.04.2026 klo 08.00

IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast

IRLAB Therapeutics
Regulatory press release29.04.2026 klo 17.30

IRLAB publishes the Annual Report for 2025

IRLAB Therapeutics
Regulatory press release17.04.2026 klo 10.50

Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026

IRLAB Therapeutics
Press release09.04.2026 klo 08.30

IRLAB to present at Redeye Healthcare Day 2026

IRLAB Therapeutics
Press release17.03.2026 klo 09.30

IRLAB to present clinical and preclinical data at the AD/PD™ 2026 – 20th International Conference on Alzheimer’s & Parkinson’s Diseases

IRLAB Therapeutics
Press release02.03.2026 klo 09.45

IRLAB participates in Life Science Day in Gothenburg on March 4, 2026

IRLAB Therapeutics
Press release27.02.2026 klo 15.29

Redeye: IRLAB (Q4 Review): IRL757 study on track

IRLAB Therapeutics
Regulatory press release26.02.2026 klo 12.58

IRLAB secures milestone payment for first patient dosed in Phase Ib study with IRL757 in Parkinson’s Disease

IRLAB Therapeutics
Regulatory press release25.02.2026 klo 08.00

IRLAB publishes full-year report for the period January – December 2025

IRLAB Therapeutics
Press release20.02.2026 klo 08.00

IRLAB has received scientific advisory board confirmation on next steps for pirepemat

IRLAB Therapeutics